Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The primary goal of this Phase 1 study is to determine if a new investigational drug, OS2966,
when delivered directly to the brain of adult participants with recurrent/progressive
high-grade glioma (HGG) is safe and well tolerated.
OS2966 is a therapeutic antibody blocking a cell surface receptor governing fundamental
biological processes that allow cancer cells to grow, spread and become resistant to cancer
treatment. Despite availability of new promising cancer treatments, successful treatment of
HGG has been limited by the presence of the brain's protective blood brain barrier (BBB). The
BBB is made up of tightly knit cells that block entry of several substances including cancer
treatments. To overcome this obstacle, a technique called convection-enhanced-delivery (CED)
will be utilized to deliver OS2966 directly to the site of disease. Convection-enhanced
delivery involves placement of one or more catheters into the brain tumor and
tumor-infiltrated brain in order to slowly pump a therapy into the tissue. In this study, the
Infuseon Cleveland Multiport Catheter (ICMC) will be used. The ICMC is a type of catheter
developed specifically for direct delivery of therapies to the brain.
To be eligible for this study participants must require surgical resection of their recurrent
HGG.